الملخص
Primary duodenal adenocarcinoma is a rare malignant neoplasm accounting for 0.3% of all gastrointestinal tract carcinomas. We herein present one case of duodenal adenocarcinoma after duodenal neuroendocrine carcinoma. Poorly differentiated duodenal neuroendocrine carcinoma with liver metastasis (TxNxM1) was confirmed, and eight cycles of palliative chemotherapy (5-fluorouracil/etoposide/cisplatin) were administered. The patient was then in a clinically complete response status. About 1 year later, newly developed adenocarcinoma was detected at the same site. It was completely surgically resected, and the patient was cured.
الموضوعات
Humans , Male , Middle Aged , Adenocarcinoma/diagnosis , Antineoplastic Agents/therapeutic use , Duodenal Neoplasms/diagnosis , Neoplasms, Second Primary/diagnosis , Neuroendocrine Tumors/diagnosisالملخص
PURPOSE: The administration of recombinant human growth hormone in adults with growth hormone deficiency has been known to improve metabolic impairment and quality of life. Patients, however, have to tolerate daily injections of growth hormone. The efficacy, safety, and compliance of weekly administered sustained-release recombinant human growth hormone (SR-rhGH, Declage(TM)) supplement in patients with growth hormone deficiency were evaluated. MATERIALS AND METHODS: This trial is 12-week prospective, single-arm, open-label trial. Men and women aged > or =20 years with diagnosed growth hormone deficiency (caused by pituitary tumor, trauma and other pituitary diseases) were eligible for this study. Each subject was given 2 mg (6 IU) of SR-rhGH once a week, subcutaneously for 12 weeks. Efficacy and safety at baseline and within 30 days after the 12th injection were assessed and compared. Score of Assessment of Growth Hormone Deficiency in Adults (AGHDA score) for quality of life and serum IGF-1 level. RESULTS: The IGF-1 level of 108.67+/-74.03 ng/mL was increased to 129.01+/-68.37 ng/mL (p=0.0111) and the AGHDA QoL score was decreased from 9.80+/-6.51 to 7.55+/-5.76 (p<0.0001) at week 12 compared with those at baseline. Adverse events included pain, swelling, erythema, and warmth sensation at the administration site, but many adverse events gradually disappeared during the investigation. CONCLUSION: Weekly administered SR-rhGH for 12 weeks effectively increased IGF-1 level and improved the quality of life in patients with GH deficiency without serious adverse events.
الموضوعات
Adult , Aged , Female , Humans , Male , Middle Aged , Delayed-Action Preparations , Growth Hormone/administration & dosage , Human Growth Hormone/deficiency , Prospective Studies , Recombinant Proteins/administration & dosageالملخص
Klinefelter syndrome is the most common type of genetic cause of hypogonadism. This syndrome is characterized by the presence of 1 or more extra X chromosomes. Phenotype manifestations of this syndrome are small testes, fibrosis of the seminiferous tubules, inability to produce sperm, gynecomastia, tall stature, decrease of serum testosterone and increases of luteinizing hormone and follicle stimulating hormone. Most patients with Klinefelter syndrome are tall, with slender body compositions, and reports of obesity are rare. We report the case of a 35-yr-old man with hypogonadism and morbid obesity and diabetes mellitus. He had gynecomastia, small testes and penis, very sparse body hair and his body mass index was 44.85. He did not report experiencing broken voice and was able to have erections. We conducted a chromosome study. His genotype was 47,X,+t(X;X)(p22.3;p22.3)del(X)(p11.23q11.2). In this case, the patient was diagnosed as Klinefelter syndrome. He showed rare phenotypes like morbid obesity and average height and the phenotype may be caused by the karyotype and the excess number of X chromosome. Further studies of the relationship between chromosomes and phenotype are warranted.
الموضوعات
Adult , Humans , Male , Diabetes Complications/genetics , Karyotyping , Klinefelter Syndrome/complications , Obesity, Morbid/complications , Phenotypeالملخص
Acromegaly is generally caused by a benign growth hormone (GH)-secreting pituitary adenoma. It is characterized by a wide range of complications; cardiovascular, respiratory, bone and joint, and metabolic complications. Among them, impaired glucose tolerance and diabetes mellitus, due to GH-induced insulin resistance, has been reported in approximately 16-46% and 19-56%. They are usually improved following the treatment of acromegaly, surgical or medical therapy. We report a first case of 36-year-old man who was paradoxically diagnosed with GAD antibody positive latent autoimmune diabetes in adults (LADA) after the surgical cure of acromegaly.
الموضوعات
Adult , Humans , Acromegaly , Diabetes Mellitus , Diabetes Mellitus, Type 1 , Diabetes Mellitus, Type 2 , Glucose , Growth Hormone , Insulin Resistance , Joints , Pituitary Neoplasmsالملخص
We encountered a patient with systemic lupus erythematosus that manifested as anemia and thrombocytopenia during antithyroid drug treatment. A 39-year-old woman with Graves' disease was admitted with anemia and thrombocytopenia. She had been treated with propylthiouracil, but had switched to methimazole one month prior to admission. We evaluated many possible causes and found that the patient had renal disorder and hematologic disorder, and was positive for antiphospholipid and antinuclear antibodies. She was diagnosed with systemic lupus erythematosus associated with Graves' disease and was successfully treated with corticosteroids.
الموضوعات
Adult , Female , Humans , Adrenal Cortex Hormones , Anemia , Antibodies, Antinuclear , Graves Disease , Lupus Erythematosus, Systemic , Methimazole , Propylthiouracil , Thrombocytopeniaالملخص
We encountered a patient with systemic lupus erythematosus that manifested as anemia and thrombocytopenia during antithyroid drug treatment. A 39-year-old woman with Graves' disease was admitted with anemia and thrombocytopenia. She had been treated with propylthiouracil, but had switched to methimazole one month prior to admission. We evaluated many possible causes and found that the patient had renal disorder and hematologic disorder, and was positive for antiphospholipid and antinuclear antibodies. She was diagnosed with systemic lupus erythematosus associated with Graves' disease and was successfully treated with corticosteroids.